SVR does not affect risk of autoimmune disorders in chronic hepatitis C patients
In chronic hepatitis C (CHC) patients, achieving sustained virological response (SVR) after therapy with pegylated interferon with ribavirin (PR) does not reduce the risk of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), a recent study has shown.
